MedTrace Logo

ALS Treatment Extension Study

NCT03136809 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2022-02-17

No results posted yet for this study

Summary

Treatment extension study for ALS/MND patients who participated in phase 1 study CMD-2016-001, completed assessments following six 28-day cycles of treatment, and whom the Investigator considers would benefit from continued CuATSM treatment.

Conditions

Interventions

DRUG

Cu(II)ATSM

copper-containing synthetic small molecule

Sponsors & Collaborators

  • Collaborative Medicinal Development Pty Limited

    lead INDUSTRY

Principal Investigators

  • Dominic Rowe, MD · Macquarie University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-18
Primary Completion
2022-12-31
Completion
2022-12-31
FDA Drug
Yes

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03136809 on ClinicalTrials.gov